Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

por Verstovsek, Srdan, Mesa, Ruben, Talpaz, Moshe, Kiladjian, Jean-Jacques, Harrison, Claire N., Oh, Stephen T., Vannucchi, Alessandro M., Rampal, Raajit, Scott, Bart L., Buckley, Sarah A., Craig, Adam R., Roman-Torres, Karisse, Mascarenhas, John O.
Publicado 2021

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

por Oh, Stephen T., Mesa, Ruben A., Harrison, Claire N., Bose, Prithviraj, Gerds, Aaron T., Gupta, Vikas, Scott, Bart L., Kiladjian, Jean-Jacques, Lucchesi, Alessandro, Kong, Tim, Buckley, Sarah A., Tyavanagimatt, Shanthakumar, Harder, Bryan G., Roman-Torres, Karisse, Smith, Jennifer, Craig, Adam R., Mascarenhas, John, Verstovsek, Srdan
Publicado 2023